Food and Drugs Administration (FDA) agnostic approval of dabrafenib and trametinib for BRAF V600E mutant solid tumors on 22nd June 2022 opens the door to targeted therapy in this subset of patients [15], including rare cancers as malignant GT, where other therapeutic options could not be effective or available. Here, BRAF is linked to cancer.